Emir Duzic to Head GPCR Assay Services for ChanTest Corporation

CLEVELAND--(BUSINESS WIRE)-- Emir Duzic, Ph.D. has joined ChanTest Corporation as head of GPCR and HTS Assay Services. In his new role, Dr. Duzic has overall responsibility for developing, optimizing, standardizing and running all GPCR assays for customer compounds and all GPCR research projects. ChanTest recently expanded its GPCR cell lines, adding 57 for a total of 127. In addition to GPCRs, Dr. Duzic will direct all HTS campaigns for Ion Channels.

Dr. Duzic came to ChanTest from Cephalon, Inc., West Chester, Pennsylvania, where he was associate director of the Molecular and Cellular Pharmacology Unit. Prior to Cephalon, he served as associate director of the Cellular Biology Unit at Millennium Pharmaceuticals in Cambridge, Massachusetts. Dr. Duzic has extensive experience in GPCR pharmacology and signaling, in discovery of small molecule clinical candidates for targeted GPCRs and HTS campaigns and is considered a leader in preclinical in vitro drug discovery.

Dr. Duzic, whose career included two years of research at the former Lederle Laboratories (acquired by Wyeth-Ayerst, now Pfizer), also served four years as group leader, then associate director of Receptor Pharmacology and Biochemistry at Cadus Pharmaceutical Corporation in New York. He was the recipient of several Fellowship Awards and throughout the years Dr. Duzic has been a prolific lecturer and journal author who has secured five patents. His educational background includes the University of Sarajevo, Harvard Medical School and the Medical University of South Carolina.

“We are pleased to welcome Emir Duzic to our management team. He will play a critical role in the growth and development of our GPCR assays and HTS campaigns with either Ion Channel or GPCR targets, both key strategic initiatives for us at this time,” said Dr. Arthur “Buzz” Brown, CEO of ChanTest.

About ChanTest Corporation (www.chantest.com)

ChanTest’s mission is to serve the research, drug discovery and drug development needs of customers worldwide with high-value solutions for Ion Channel and GPCR biology. Since its inception in 1998, the company has tested compounds for more than 500 global pharmaceutical and biotechnology companies and partners with them to speed the drug development process for the release of better, safer drugs. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines and pre-clinical cardiac risk assessment service portfolio are the most comprehensive commercially available today. Because of ChanTest’s seminal role in the pre-clinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in an independent survey for the past three years. ChanTest is based in Cleveland, Ohio. For more information, e-mail [email protected].



CONTACT:

MEDIA:
Reese A. Nank, APR
Reputations PR and Marketing
410-218-9121
[email protected]
or
COMPANY:
Mark Keck
ChanTest Corporation
216-332-1665
[email protected]

KEYWORDS:   United States  North America  Ohio

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  Cardiology  Clinical Trials  Genetics  Oncology  Pharmaceutical  Research  Science  General Health

MEDIA:

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.